We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports.

In 2014 Ramaswamy co-founded Roivant Sciences, which buys or licenses promising drugs and develops them. Ramaswamy reported nearly $175 million in capital gains from a $3 billion deal Roivant cut ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other cash-rich mid cap stocks. Cash flow is the money moving in and out of a business ...